Brian T Fife

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal
    Brian T Fife
    UCSF Diabetes Center, Department of Medicine, University of California, San Francisco, California, USA
    Nat Immunol 10:1185-92. 2009
  2. ncbi Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway
    Brian T Fife
    UCSF Diabetes Center, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, and Transplantation Research Center, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Exp Med 203:2737-47. 2006
  3. ncbi Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice
    Craig Meagher
    Diabetes Center, University of California, San Francisco, CA 94143, USA
    J Immunol 180:7793-803. 2008
  4. ncbi Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice
    Qizhi Tang
    Diabetes Center, Department of Medicine, University of California, San Francisco 94143, USA
    Nat Immunol 7:83-92. 2006
  5. ncbi Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist
    Brian T Fife
    UCSF Diabetes Center, Department of Medicine, UCSF, San Francisco, California 94143, and Department of Internal Medicine, Division of Nephrology, Mayo Clinic, Rochester, Minnesota, USA
    J Clin Invest 116:2252-61. 2006
  6. ncbi Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
    Brian T Fife
    Department of Medicine, UCSF Diabetes Center, University of California, San Francisco, CA 94113, USA
    Immunol Rev 224:166-82. 2008
  7. ncbi Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity
    Xuyu Zhou
    Diabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA
    J Exp Med 205:1983-91. 2008
  8. ncbi Expression of αvβ8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice
    Andrew C Melton
    Lung Biology Center, Department of Medicine, University of California, San Francisco, California, USA
    J Clin Invest 120:4436-44. 2010
  9. ncbi The role of the PD-1 pathway in autoimmunity and peripheral tolerance
    Brian T Fife
    Department of Medicine, Division of Rheumatic and Autoimmune Diseases, Center for Immunology, University of Minnesota, Minneapolis, Minnesota, USA
    Ann N Y Acad Sci 1217:45-59. 2011

Collaborators

Detail Information

Publications9

  1. ncbi Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal
    Brian T Fife
    UCSF Diabetes Center, Department of Medicine, University of California, San Francisco, California, USA
    Nat Immunol 10:1185-92. 2009
    ..Blockade of the immunomodulatory receptor CTLA-4 did not alter T cell motility or abrogate tolerance. Thus, PD-1-PD-L1 interactions maintain peripheral tolerance by mechanisms fundamentally distinct from those of CTLA-4...
  2. ncbi Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway
    Brian T Fife
    UCSF Diabetes Center, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, and Transplantation Research Center, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Exp Med 203:2737-47. 2006
    ....
  3. ncbi Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice
    Craig Meagher
    Diabetes Center, University of California, San Francisco, CA 94143, USA
    J Immunol 180:7793-803. 2008
    ..CD28KO mice provides an excellent model for the study of disease pathogenesis and development of new therapies for human autoimmune pancreatitis...
  4. ncbi Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice
    Qizhi Tang
    Diabetes Center, Department of Medicine, University of California, San Francisco 94143, USA
    Nat Immunol 7:83-92. 2006
    ..Such persistent T(reg) cell-dendritic cell contacts preceded the inhibition of T(H) cell activation by dendritic cells, supporting the idea that dendritic cells are central to T(reg) cell function in vivo...
  5. ncbi Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist
    Brian T Fife
    UCSF Diabetes Center, Department of Medicine, UCSF, San Francisco, California 94143, and Department of Internal Medicine, Division of Nephrology, Mayo Clinic, Rochester, Minnesota, USA
    J Clin Invest 116:2252-61. 2006
    ....
  6. ncbi Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
    Brian T Fife
    Department of Medicine, UCSF Diabetes Center, University of California, San Francisco, CA 94113, USA
    Immunol Rev 224:166-82. 2008
    ....
  7. ncbi Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity
    Xuyu Zhou
    Diabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA
    J Exp Med 205:1983-91. 2008
    ..These results support a central role for miRNAs in maintaining the stability of differentiated T reg cell function in vivo and homeostasis of the adaptive immune system...
  8. ncbi Expression of αvβ8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice
    Andrew C Melton
    Lung Biology Center, Department of Medicine, University of California, San Francisco, California, USA
    J Clin Invest 120:4436-44. 2010
    ..Our results therefore suggest that the integrin αvβ8 pathway is biologically important and that αvβ8 expression on DCs could be a therapeutic target for the treatment of Th17-driven autoimmune disease...
  9. ncbi The role of the PD-1 pathway in autoimmunity and peripheral tolerance
    Brian T Fife
    Department of Medicine, Division of Rheumatic and Autoimmune Diseases, Center for Immunology, University of Minnesota, Minneapolis, Minnesota, USA
    Ann N Y Acad Sci 1217:45-59. 2011
    ..Finally, we discuss the potential to selectively target the PD-1 pathway therapeutically to alter T cell function during autoimmunity...